Progression-free survival (PFS) and overall survival (OS) among <i>ALK-</i>positive patients, patients who have <i>EGFR</i> activating mutations and wild type both <i>ALK</i> and <i>EGFR</i> (WT/WT).

<p>(A) PFS for patients receiving the first-line chemotherapy harboring <i>ALK</i> rearrangements, <i>EGFR</i> activating mutations, and WT/WT. (B) PFS for patients receiving EGFR TKIs harboring <i>ALK</i> rearrangements, <i>EGFR</i> activating mutations, and WT/WT. (C) OS for patients harboring <i>ALK</i> rearrangements, <i>EGFR</i> activating mutations, and WT/WT.